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The basal forebrain cholinergic system (BFCS) plays a role in several aspects of attentional
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function. Activation of this system by different afferent inputs is likely to influence how

Available online 21 August 2009

attentional resources are allocated. While it has been recognized for some time that the
hypothalamus is a significant source of projections to the basal forebrain, the phenotype(s)
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of these inputs and the conditions under which their regulation of the BFCS becomes
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functionally relevant are still unclear. The cell bodies of neurons expressing orexin/

Orexin

hypocretin neuropeptides are restricted to the lateral hypothalamus and contiguous

Hypocretin

perifornical area but have widespread projections, including to the basal forebrain. Orexin

Basal forebrain

fibers and both orexin receptor subtypes are distributed in cholinergic parts of the basal

Attention

forebrain, where application of orexin peptides increases cell activity and cortical

Arousal

acetylcholine release. Furthermore, disruption of orexin signaling in the basal forebrain
impairs the cholinergic response to an appetitive stimulus. In this review, we propose that
orexin inputs to the BFCS form an anatomical substrate for links between arousal and
attention, and that these interactions might be particularly important as a means by which
interoceptive cues bias allocation of attentional resources toward related exteroceptive
stimuli. Dysfunction in orexin–acetylcholine interactions may play a role in the arousal and
attentional deficits that accompany neurodegenerative conditions as diverse as drug
addiction and age-related cognitive decline.
© 2009 Elsevier B.V. All rights reserved.

1.

Introduction

Since the first reports of their discovery in the late 1990s
(de Lecea et al., 1998; Sakurai et al., 1998) the orexin/hypocretin
family of neuropeptides has generated a tremendous amount
of interest due to their involvement in a variety of important
and interesting physiological phenomena, leading to their
description as “physiological integrators” (de Lecea et al., 2002).
The cell bodies of orexin/hypocretin neurons are confined to

the lateral hypothalamus and contiguous perifornical area,
although they project widely to both rostral and caudal brain
regions (Peyron et al., 1998). The peptides produced by the
preproorexin gene act on two G protein-coupled receptors: the
orexin/hypocretin 1 receptor (Ox1R/HcrtR1), which is selective
for orexin A (OxA)/hypocretin 1, and the orexin 2 receptor
(Ox2R/HcrtR2), which binds both OxA and orexin B/hypocretin
2 (OxB) with high affinity (Ammoun et al., 2003; Sakurai et al.,
1998). More definitive descriptions of the specific roles played
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by these peptides (hereafter referred to as orexins, for
simplicity) in certain normal and pathological neural processes will be facilitated by further analysis of their interactions
with other brain regions and neurotransmitter systems. The
anatomical substrates for these interactions, including for
those underlying the putative effects of orexins on attention
(the focus of this review), are multitudinous (Peyron et al.,
1998). Orexins likely regulate attention and arousal via
interactions with a variety of ascending neuromodulatory
systems, including dopamine neurons in the ventral midbrain
(Fadel and Deutch, 2002; Vittoz and Berridge, 2006) and
noradrenergic neurons in the locus coeruleus (Baldo et al.,
2003; Espana et al., 2005; Horvath et al., 1999). Our labs,
however, have focused primarily on orexin interactions with
the basal forebrain cholinergic system (BFCS), the principle
extrinsic source of the neurotransmitter acetylcholine (ACh) in
the mammalian neocortex and a crucial mediator of several
aspects of attentional function. We propose that orexin inputs
to the BFCS form an anatomical substrate for links between
arousal and attention, and that these interactions might be
particularly important as a means by which interoceptive cues
bias allocation of attentional resources toward related exteroceptive stimuli.

2.
Overview of the basal forebrain cholinergic
system role in attention
Attention represents a construct that can be defined and
measured based upon manipulation of specific variables,
including target number, duration and unpredictability along
with the ability to ignore irrelevant stimuli (Parasuraman et al.,
1987; Sarter et al., 2001). As has been discussed in other reviews
(Sarter et al., 2001), attentional processing requires some
generalized state of arousal, or a general physiological state of
readiness for action. However, brain mechanisms involved in
attention can be dissociated from arousal based upon changes
in task performance following manipulation of specifically
defined variables known to affect attentional processing.
The BFCS is composed of a group of magnocellular, AChutilizing neurons distributed among heterogeneous anatomical structures along the ventral aspect of the mammalian
forebrain. This system includes a loosely clustered arrangement of cholinergic neurons located in the nucleus basalis
magnocellularis (nBM) and rostrally contiguous ventral pallidum/substantia innominata (VP/SI), termed the Ch4 subgroup
by Mesulam et al. (1983a,b). These neurons project diffusely to
all layers and areas of the neocortical mantle (Bigl et al., 1982),
where the primary physiological effect of ACh is to modulate
the response of pyramidal cells to other, particularly glutamatergic, cortical input (McCormick, 1993; Metherate and
Ashe, 1993). This innervation of the neocortex by basal
forebrain cholinergic neurons is an important mediator of
cortical activation in support of cognitive function.
The available evidence suggests that multiple aspects of
attention are dependent upon cortical cholinergic inputs
arising from the basal forebrain. Pharmacological manipulations of cholinergic receptors in humans are known to affect
attentional performance (Bentley et al., 2004). In animals,
lesion studies, particularly those employing the immuno-
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toxin, 192 IgG-saporin, which selectively destroys cortically
projecting basal forebrain cholinergic neurons in rats, have
been useful for demonstrating the necessity of the BFCS for
attention (McGaughy et al., 2000). For example, accuracy of
visual signal detection is decreased in attention-demanding
tasks following loss of basal forebrain corticopetal cholinergic
neurons (McGaughy et al., 2002, 1996). Performance in divided
attention paradigms is also disrupted following intrabasalis
infusions of 192 IgG-saporin (Turchi and Sarter, 1997).
Moreover, cortical acetylcholine release is elevated during
attentional task performance compared with control tasks
that limit explicit attentional demands, but that do require
similar levels of motoric functioning and that provide similar
reinforcement schedules as the attention-demanding task
(Arnold et al., 2002; Dalley et al., 2001; Passetti et al., 2000).
Thus, the actions of orexins within the basal forebrain on
attention can potentially be dissociated with other nonspecific
task variables.

3.
Anatomical substrates of orexin modulation
of the basal forebrain cholinergic system
A series of important primate studies from the 1970s showed
that (putatively cholinergic) basal forebrain neurons respond
to food-related visual stimuli only when the animal is hungry
(Burton et al., 1976; Mora et al., 1976; Rolls et al., 1977, 1979).
These observations provided a clear demonstration that the
interoceptive state of an animal modulates the response to
sensory cues related to physiological status. In other words,
homeostatic drive modulates the appetitive salience of a
stimulus and the response of neural circuitry underlying
attention to that stimulus. While this may seem intuitive,
thorough anatomical and phenotypical descriptions of the
neural substrates of this relationship have not been forthcoming. What are the neuroanatomical substrates by which
information related to physiological status is relayed to
neuromodulatory systems involved in attention?
The primary central structure mediating the brain's detection of—and response to—physiological cues from the periphery is the hypothalamus. While the lateral hypothalamus has
been classically conceptualized as a “feeding center,” it is also
part of the posterior hypothalamus, a major component of the
mammalian arousal system (Jones, 2003; Lin et al., 1989;
Robinson and Whishaw, 1974; Swett and Hobson, 1968). Thus,
this hypothalamic area may be involved in supporting the
autonomic and behavioral responses necessary for homeostatic regulation. Because attention, or the ability to detect and
select relevant stimuli, requires a generalized state of physiological readiness, i.e., arousal (Robbins, 1997), the afferent
regulation of the BFCS by brain regions active in the establishment or maintenance or arousal is of major significance.
Projections from the lateral hypothalamus to the cholinergic basal forebrain have been well-documented and have been
hypothesized to relay interoceptive information to this area
(Cullinan and Zaborszky, 1991; Zaborszky and Cullinan, 1989).
However, phenotypic and functional descriptions of the pathways by which the lateral hypothalamus relays information to
rostral brain regions involved in cognitive function have only
begun to be elucidated in recent years. As more is learned
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about the phenotype and function of ascending hypothalamic
projections to areas such as the basal forebrain, a greater
appreciation of the role played by these pathways in cognitive
and behavioral correlates of age-related hypothalamic dysfunction is likely to emerge.
In recent years a clear anatomical substrate for interactions
between orexin neurons and the BFCS has been documented.
Hypothalamic projections to cholinergic parts of the basal
forebrain were originally described as originating in the farlateral and medial parts of the lateral hypothalamus (Cullinan
and Zaborszky, 1991), a pattern that roughly corresponds to the
location of orexin neurons. Indeed, orexin-immunoreactive
fibers in the rat distribute widely to various basal forebrain
structures (Cutler et al., 1999; Date et al., 1999; Peyron et al.,
1998); included among these basal forebrain targets is the

substantia innominata, which receives a predominantly
ipsilateral orexin input (Espana et al., 2005). Because cholinergic neurons of the basal forebrain are not confined to a
single, well-circumscribed nucleus, it was important for these
orexin inputs to be further characterized specifically with
regard to the phenotype of their postsynaptic targets. Orexinimmunoreactive fibers in the substantia innominata and
contiguous ventral pallidum make apparent appositional
contacts on ChAT-positive, as well as parvalbumin-positive,
cells (Fadel et al., 2005) (see also Fig. 1), suggesting the potential
for a direct influence of orexins over corticopetal cholinergic
and GABAergic projections. While the existence of these
postulated monosynaptic connections between orexin fibers
and cholinergic neurons awaits ultrastructural confirmation,
a combined electron and light microscopic study in the

Fig. 1 – Examples of orexin innervation of cholinergic and GABAergic neurons of the basal forebrain. All photomicrographs
were taken from the ventral pallidum/substantia innominata region of the adult (age 3 months) rat basal forebrain (D), following
dual-color immunoperoxidase histochemistry using previously described methods (Fadel and Deutch, 2002; Frederick-Duus
et al., 2007). (A–C) Double-labeling for ChAT (light brown cell body) and orexin A (black fibers). Arrows indicate points of putative
appositional contact between orexin fibers and a cholinergic neuron. Scale bar represents approximately 25 μm. (B) and (C)
show different focal planes from the same region, indicating multiple putative z-plane contacts on the proximal dendrite (B) and
soma (C) of the same neuron. (E) Double-labeling for the calcium-binding protein parvalbumin (light brown cell bodies), which
marks a subset of GABAergic corticopetal basal forebrain neurons, and orexin A (black fibers). Again, orexin fibers are found in
high abundance in this region of the basal forebrain, including on and around GABAergic neurons.
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brainstem dorsal raphe nucleus has shown that orexinimmunoreactive varicosities observed at the light microscopic
level have the ultrastructural appearance of presynaptic axon
terminals, with numerous dense core vesicles (Wang et al.,
2003). Thus, these varicosities likely represent functional
orexin synapses on and around cholinergic somata and
perikarya as has already been described for septohippocampal
cholinergic neurons (Wu et al., 2004). In addition, retrograde
tracer deposits in the basal forebrain label many non-orexin
neurons in the area of the lateral hypothalamus (Pasumarthi
and Fadel, 2008); although the phenotype of these basal
forebrain-projecting, non-orexin neurons remains to be determined, they may represent an additional source of hypothalamic regulation of the BFCS in the context of homeostatic
function. However, the available anatomical data clearly
demonstrate that orexin neurons contribute substantially to
the previously recognized projection from the lateral hypothalamus to the cholinergic basal forebrain (Cullinan and
Zaborszky, 1991), implicating the basal forebrain as an integral
component of a distributed network that underlies orexin
effects on arousal and attention (Espana et al., 2005).

4.
Orexin regulation of basal forebrain
cholinergic system activity
Functional descriptions of the importance of orexin–BFCS
interactions have derived from electrophysiological, neurochemical and behavioral studies. Although brain orexin levels
in general tend to be greatest during wakeful periods,
microdialysis across the sleep–wake cycle reveals significant
increases in basal forebrain release of OxA during paradoxical,
or rapid eye movement (REM) sleep (Kiyashchenko et al., 2002).
Electrophysiological data suggest that this may reflect burst
discharge of orexin neurons during phasic REM as these cells
are largely silent during tonic REM (Mileykovskiy et al., 2005),
although given the different time scales of microdialysis and
juxtacellular recordings, this relationship between burst
discharge and orexin release remains speculative. REM sleep
is also associated with activation of corticopetal cholinergic
neurons (Jones, 2003; Szyjmusiak, 1995), suggesting a potential
role for orexins in this phenomenon. Clearly, however, Fos
expression and in vivo electrophysiological data both indicate
a high level of orexin neuron activity during transitions to
wakefulness (Estabrooke et al., 2001; Lee et al., 2005). Similarly,
intrabasalis administration of OxA via reverse microdialysis or
direct intracranial infusion increases behavioral indices of
wakefulness (Espana et al., 2001; Thakkar et al., 2001).
Intrabasalis administration of orexin A produces robust
increases in ACh release within the PFC (Fadel et al., 2005)
and amplifies the effects of pedunculopontine tegmentum
stimulation on electroencephalograph desynchrony (Dong
et al., 2006), suggesting that orexins may increase arousal via
complementary and synergistic effects on both basal forebrain
and brainstem cholinergic systems (Bernard et al., 2006;
Vazquez and Baghdoyan, 2001).
Orexin A activates both types of orexin receptors with
roughly equal affinity; hence, effects of this peptide on the
basal forebrain cholinergic system do not point to a specific
receptor subtype. Furthermore, both Ox1R and Ox2R appear to
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be expressed in parts of the basal forebrain that include
corticopetal cholinergic neurons (Hervieu et al., 2001; Kilduff
and de Lecea, 2001; Marcus et al., 2001) and electrophysiological and neurochemical data are consistent with a role for
both Ox1R and Ox2R in activation of the basal forebrain
cholinergic system. In vitro electrophysiological data indicate
that OxB is at least as potent as OxA at exciting basal forebrain
cholinergic cells, suggesting primarily an Ox2R-mediated
effect (Eggermann et al., 2001). These observations place the
basal forebrain cholinergic system within the distributed
network underlying the effects of orexins on arousal and
wakefulness, as the narcoleptic phenotype associated with
loss of orexin neurons or peptides in humans and mice is
largely recapitulated in narcoleptic canines with a spontaneously occurring loss-of-function mutation in Ox2R (Lin
et al., 1999). However, other studies have suggested that the
effects of basal forebrain orexin administration on wakefulness are largely Ox1R-mediated. Lateral ventricular administration of OxA, for example, is more effective than OxB at
increasing electroencephalographic, electromyographic and
behavioral indices of wakefulness, and these effects are
recapitulated with direct intrabasalis administration of OxA
(Espana et al., 2001). Also, in anesthetized rats, intrabasalis
administration of OxA is more effective than OxB at increasing somatosensory cortical ACh release and inducing an
arousal-like electroencephalograph pattern (Dong et al., 2006).
Our studies on the effects of orexins on cortical cholinergic
transmission are also consistent with an Ox1R mechanism, as
stimulated cortical ACh release under conditions tied to
feeding-related arousal is largely blocked by the Ox1R
antagonist, SB-334867 (Frederick-Duus et al., 2007). In addition
to a primary effect mediated by direct activation of orexin
receptors on cholinergic neurons, this may reflect the ability
of OxA to increase glutamate release within the basal
forebrain (Fadel and Frederick-Duus, 2008). While ultrastructural studies definitively demonstrating the presence of
presynaptic orexin receptors on glutamatergic terminals in
the basal forebrain have not been reported, these receptors
are expressed in sources of presumptive glutamatergic inputs
to the basal forebrain, including the prefrontal and insular
cortices (Hervieu et al., 2001; Marcus et al., 2001). Ox1R is also
expressed in orexin neurons themselves (Backberg et al.,
2002), at least some of which colocalize glutamate (Rosin et al.,
2003; Torrealba et al., 2003). Finally, several electrophysiological studies have suggested the ability of orexin to increase
presynaptic glutamate release in other orexin-receptive brain
regions, including the PFC (Lambe et al., 2007), VTA (Borgland
et al., 2008) and preoptic area (Kolaj et al., 2008). Collectively,
these studies support the hypothesis that, in addition to direct
effects, orexins may excite basal forebrain cholinergic neurons via presynaptic glutamatergic mechanisms.
The current data do not allow for definitive conclusions
regarding which of the orexin receptor subtypes is most
heavily involved in activation of the BFCS. Indeed, the two
receptors may play different, but complementary roles in
response to varying types of homeostatic challenges. Ultrastructural studies documenting the precise presynaptic and
postsynaptic localization of Ox1R and Ox2R within the basal
forebrain as well as commercial availability of additional
selective agonists and antagonists of these receptors will
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provide much-needed anatomical and pharmacological data
concerning the mechanisms and functional contexts underlying orexin effects on basal forebrain cholinergic neurons.

5.
Physiological determinants of orexin–ACh
interactions
Given the integrative role of orexin neurons, characterizing the
specific contribution of these peptides to activation of the BFCS
in response to cues related to physiological homeostasis is
important. Orexin neurons are sensitive to a number of
peripherally derived circulating factors whose fluctuations
provide information about homeostatic status, including
leptin, ghrelin and glucose (Burdakov and Gonzalez, 2009;
Burdakov et al., 2006; Hakansson et al., 1999; Sakurai, 2005).
Food deprivation increases expression of orexin peptides and/
or receptors (Kurose et al., 2002; Lu et al., 2000) and orexins are
important for food anticipatory-related arousal in fasted
animals (Akiyama et al., 2004; Mieda et al., 2004), strongly
implicating the orexin system in cholinergic activation by
stimuli of homeostatic relevance. Consistent with this hypothesis, we have shown that the normal, robust, cholinergic
response to palatable food reward in food-restricted rats is
dramatically blunted by pretreatment with the Ox1R antagonist
SB-334867 or by immunotoxic lesions that destroy orexin
neurons (Frederick-Duus et al., 2007). Importantly, the SB334867 effects were recapitulated by intrabasalis administration of the drug, indicating that orexin regulation of the BFCS
under these conditions does not merely reflect transsynaptic
effects mediated by brainstem arousal systems. Furthermore,
behaviorally, Ox1R antagonism is associated with increased
latency to approach and consume a food reward. It has been
suggested that orexin effects on feeding are secondary to their
role in regulating arousal threshold (Sutcliffe and de Lecea,
2002). A cognitive correlate to this hypothesis is that orexins, via
interactions with areas such as the BFCS, are important for
attention to both the interoceptive components of a physiological challenge (“How do I feel?”) and the detection and
processing of exteroceptive stimuli related to interoceptive
state (“Which sensory cues in my environment are salient?”).
Accordingly, ascending inputs to the orexin neurons suggest
substrates for regulation beyond those limited to metabolic
cues, but also derive from brainstem regions that may convey
information regarding arousal, pain and visceral status (Sakurai
et al., 2005; Yoshida et al., 2006). Psychological stress states,
such as those that accompany fear and anxiety, may represent
an additional interoceptive cue whose autonomic, behavioral
and cognitive correlates may depend in part on the orexin
system (Lambe et al., 2007; Mathew et al., 2008). Neurotoxic
lesions of the perifornical hypothalamus, for example, abolish
the cardiovascular and behavioral components of conditioned
fear (Furlong and Carrive, 2007). Interestingly, our recent
preliminary data indicate that orexin neurons are also activated
by the anxiogenic benzodiazepine partial inverse agonist FG7142 (Fig. 2), whose autonomic and cognitive effects are
mediated in part via the basal forebrain cholinergic system
(Berntson et al., 1996; Moore et al., 1995). Orexin neurons, then,
are strategically located to regulate the activity of the BFCS in
response to a wide variety of interoceptive cues. Disruptions in

Fig. 2 – Activation of orexin neurons by FG-7142. Adult
male rats were treated acutely with the anxiogenic
benzodiazepine partial inverse agonist FG-7142 (8. 0 mg/kg;
i.p.) or vehicle and sacrificed 2 h later. Brains were processed
for double-label immunohistochemistry for Fos (black nuclei)
and orexin (light brown cytoplasmic staining) using
previously described methods (Fadel et al., 2002; Pasumarthi
and Fadel, 2008). Few double-labeled cells are seen following
vehicle treatment (A). FG-7142 treatment (B) produced a
robust activation of perifornical orexin neurons as seen in
this cluster of double-labeled cells (arrows). Scale bar
represents approximately 100 μm.

these interactions may contribute to attentional dysfunction in
a variety of neuropsychiatric conditions, as discussed below.

6.

Orexin regulation of attention

Alterations of attentional processing related to disruptions of
cholinergic functioning have been associated with numerous
neuropsychiatric disorders, including Alzheimer's disease,
schizophrenia and drug addiction (Brousseau et al., 2007;
Field and Cox, 2008; Sarter et al., 2005b). Attentional dysfunction may lead to disruptions of working memory or bias
processing for specific environmental cues (Sarter et al., 2005a;
Sarter and Turchi, 2002). Thus, disrupted attention may
contribute to other symptoms associated with some disorders.
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We have reported that systemic administration of the OX1R
antagonist, SB-334867, decreases signal detection in a twolever attention task requiring discrimination of visual signals
from trials with no signal presentation (Boschen et al., 2009)
(see also Fig. 3). A similar pattern of impairment, a decrease in
signal detection, has been reported following loss of basal
forebrain corticopetal cholinergic neurons (McGaughy et al.,
1999, 1996). When SB-334867 was administered directly into
the basal forebrain before performance in this task, we

observed decreases in an overall measure of accuracy that
takes into account performance on trials with signals and
without signal presentation. Thus, intrabasalis SB-334867 also
produced a marginal decrease in accuracy on no signal trials.
Ibotenic acid-induced basal forebrain lesions, which produce
relatively greater damage to non-cholinergic basal forebrain
neurons compared to cholinergic neurons, also decrease
accuracy in this task on trials when no signal is presented
(Burk and Sarter, 2001). Thus, we concluded that orexinergic
inputs onto cholinergic and non-cholinergic basal forebrain
neurons represent an important system for regulating attentional processing. Interactions between cortical ACh and GABA
have been discussed, but remain poorly understood (Sarter and
Bruno, 2002). Prefrontal cortical inputs to the basal forebrain
make synapses onto neurons that putatively release GABA
(Gritti et al., 1997; Zaborszky et al., 1997). Collectively, the
available evidence suggests that orexinergic inputs can modulate basal forebrain cholinergic and non-cholinergic neurons,
which may, in turn, affect prefrontal cortical processing.
Dysregulation of orexin inputs to the basal forebrain may
contribute to attentional deficits in some disorders, as discussed in more detail below. Orexins have also been implicated
in learning and memory, with orexin A enhancing performance
in active and passive avoidance procedures (Jaeger et al., 2002;
Telegdy and Adamik, 2002). Cortical cholinergic inputs have
been hypothesized to contribute to learning and memory,
particularly in tasks that place high demands on attentional
processing (Sarter et al., 2003). Thus, alterations in attention
associated with pharmacological manipulation of orexin
receptors may contribute to some of the effects of orexins on
learning and memory (Boschen et al., 2009; Sarter et al., 2003).
However, caution is warranted in these conclusions as the
effects of orexin A or B administration on performance in
attention-demanding tasks have not been reported.

7.

Fig. 3 – Effects of orexin-1 receptor blockade on attentional
performance. The figure depicts the significant effects
of systemic (A) or intrabasalis (B) SB-334867 in an
attention-demanding task that required discrimination of
brief visual signals from trials with no signal presentation.
Systemic SB-334867 (5.0 mg/kg; i.p.) significantly decreased
signal detection following the 500-ms signal (relative hits;
denoted by the asterisk), effects similar to those observed
following loss of basal forebrain corticopetal cholinergic
inputs (McGaughy et al., 1999; McGaughy and Sarter, 1998).
Intrabasalis SB-334867 (60 μg) decreased accuracy on a
sustained attention (SAT) measure, which takes into account
accuracy on trials with and without signal presentation
(denoted by the asterisk). This decrease in overall accuracy
may reflect that SB-334867 also affected non-cholinergic
basal forebrain corticopetal cholinergic neurons (Burk and
Sarter, 2001; Sarter and Bruno, 2002). The figure is modified
from Boschen et al. (2009). Error bars represent SEMs.
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Narcolepsy

Post-mortem studies have clearly demonstrated that human
narcolepsy is associated with a loss of orexin peptides
(Nishino et al., 2000; Peyron et al., 2000; Thannickal et al.,
2000). Similarly, the spontaneously occurring form of canine
narcolepsy is associated with a loss-of-function mutation in
Ox2R (Lin et al., 1999) and orexin knockout mice display a
narcoleptic phenotype (Chemelli et al., 1999). Interestingly,
narcoleptic patients demonstrate attentional deficits even
during periods of normal wakefulness (Naumann et al., 2006;
Rieger et al., 2003), consistent with a role for the orexin system
in some aspects of cognition. Canine narcolepsy is also
associated with neurodegeneration in parts of the basal
forebrain (Siegel et al., 1999), suggesting that a primary deficit
in orexin signaling might contribute to postsynaptic degeneration and impaired ACh-dependent cognitive function.

8.

Drug addiction and relapse

A clear role is emerging for the orexin system in responses to
drugs of abuse. Orexin neurons are activated by a variety of
psychostimulant drugs, including nicotine (Pasumarthi et al.,
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2006), amphetamine (Fadel et al., 2002), methamphetamine
(Estabrooke et al., 2001) and the wake-promoting drug modafinil (Scammell et al., 2000). Morphine-conditioned place
preference is associated with activation of lateral hypothalamic orexin neurons in a manner that suggests the involvement of this subgroup of orexin neurons in reward (Harris et al.,
2005, 2007). Orexin transmission in the VTA appears to play an
essential role in the physiological and behavioral correlates of
repeated cocaine administration (Borgland et al., 2006). Furthermore, an Ox1R antagonist has recently been shown to
attenuate self-administration of nicotine in rats, perhaps via
circuitry involving the insular cortex (Hollander et al., 2008).
What role might orexin actions in the basal forebrain
cholinergic system play in these phenomena?
We have recently shown that acute nicotine administration
increases expression of the immediate-early gene product,
Fos, in orexin neurons that project to the basal forebrain and
paraventricular nucleus of the dorsal thalamus (Pasumarthi
and Fadel, 2008). This suggests that ascending orexin projections may be important for coordinating the arousal and
attentional correlates of nicotine administration. Repeated
nicotine or amphetamine administration sensitizes cortical
ACh release and the behavioral correlates of this neurochemical response suggest that this may underlie alterations of
attentional processing (Arnold et al., 2003; Deller and Sarter,
1998; Nelson et al., 2000). Similarly, the ability of insular cortex
SB-334867 to block nicotine self-administration (Hollander
et al., 2008) is consistent with clinical data pointing to an
important role of the insula in nicotine addiction (Naqvi et al.,
2007) as well as the hypothesized role of this cortical region in
interoception (Craig, 2002). In addition to serving as a site of
convergence of cholinergic and orexin inputs, the insular
cortex is a major source of cortical projections back to the basal
forebrain in primates and rodents (Carnes et al., 1990; Mesulam
and Mufson, 1984; Zaborszky et al., 1997). Collectively, this
suggests that orexins may coordinate attention to interoceptive and exteroceptive cues related to psychostimulant drugs
of abuse (Fig. 4). Interestingly, orexin neurons appear to receive
a reciprocal innervation from cholinergic neurons of the basal
forebrain (Sakurai et al., 2005), and ACh depolarizes orexin
neurons (Yamanaka et al., 2003). Recent studies in our lab
demonstrate that nicotine increases ACh release in the LH/PFA
(Pasumarthi and Fadel, 2006), suggesting that, in addition to
the effect of orexins on the BFCS, cholinergic inputs to the
hypothalamus may recruit orexin neurons in a “top-down”
fashion, allowing for enhancement of general arousal in
response to the detection of salient external cues.
It is becoming increasingly clear that the orexin system
plays a crucial role in the neuroplasticity that underlies
several aspects of repeated psychostimulant administration
in animal models (Bonci and Borgland, 2009; Borgland et al.,
2006; Boutrel et al., 2005; Wang et al., 2009). The absence of
orexin neurons in narcoleptic patients with cataplexy has
been suggested to underlie anecdotal reports of the reduced
susceptibility of these patients to stimulant abuse and
addiction (Zeitzer et al., 2006). Psychostimulant abuse can
produce “hyper-attentional” impairments—defined as the
compulsive processing of drug-related cues to the exclusion
of other environmental cues—that may predispose to relapse
by pathological processing of drug-related stimuli (Jovanovski

Fig. 4 – Hypothetical summary model of orexin regulation of
cholinergic projections to prefrontal (PFC) and insular (IC)
cortices, based on known anatomical relationships. ACh
neurons from the basal forebrain cholinergic system (BFCS)
have widespread cortical projections, including to PFC and IC.
The involvement of the PFC in executive function and the
putative role of the IC as “interoceptive cortex” suggest that
the BFCS may influence exteroceptive and interoceptive
attention via projections to these areas, respectively. Orexin
neurons of the lateral hypothalamus and perifornical area
(green stars), as integral components of the hypothalamic
circuitry responsive to physiological signals, may allow for
coordinated activation of rostral attentional circuitry,
ultimately allowing for biased allocation of attentional
resources toward stimuli related to physiological status.
Alterations in these interactions may contribute to a number
of neuropsychiatric conditions in which individual
components of these pathways have been implicated,
including drug addiction or relapse and the anorexia of aging.

et al., 2005). These impairments have been hypothesized to be
mediated through the BFCS, suggesting a possible role for
orexin–ACh interactions (Nelson et al., 2000; Sarter et al.,
2005a; Williams and Adinoff, 2008). Thus, it seems reasonable
to hypothesize that orexin regulation of basal forebrain
cholinergic inputs to cortical areas such as the PFC and insula
may enhance attentional processing of external, drug-related
cues and internal cues related to the aversive state that
accompanies, for example, withdrawal.

9.

Aging

There is little evidence for frank degeneration, in the form of
substantial cell loss, of the orexin system solely as a function of
age in humans or animal models. However, a compelling body
of data is beginning to accumulate suggesting that aging may
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be associated with a decline in expression of orexins or their
receptors as well as decreased innervation of certain target
structures. For example, aging is associated with decreased
Ox2R expression in several brain regions in mice (Terao et al.,
2002). Aging has also been shown to decrease levels of both
OxA and OxB, as well as their common precursor, preproorexin, in the rat brain (Porkka-Heiskanen et al., 2004). Old rats
have decreased cerebrospinal fluid orexin levels across the
sleep–wake cycle (Desarnaud et al., 2004). Altered innervation
of brainstem structures, including a decrease in orexinimmunoreactive fibers in the locus coeruleus, has been
reported (Zhang et al., 2002). Similarly, our own preliminary
data indicate that aged rats have reduced numbers of putative
appositional contacts on and around ChAT-positive cell bodies
in the basal forebrain (Frederick-Duus et al., 2008). What might
be the implications of age-related changes in the orexin
system for basal forebrain cholinergic function?
An early and consistent feature of age-related changes in
cognitive function, ranging from mild cognitive impairment to
Alzheimer's disease, is a decline in attentional capacity (Oken
et al., 1994; Sarter and Turchi, 2002; Scinto et al., 1994). These
deficits likely reflect alterations in several interacting neurotransmitter systems, including a prominent role for the
corticopetal cholinergic system (Hasselmo and McGaughy,
2004; Muir et al., 1992; Robbins et al., 1997; Sarter and Bruno,
1997; Whitehouse, 2004). However, while severe and late stage
dementia is clearly marked by a loss of cholinergic neurons and
markers of cholinergic activity (Mufson et al., 2002; Rossor et al.,
1982; Whitehouse et al., 1982), frank loss of basal forebrain
cholinergic neurons does not consistently appear to be the
earliest or most pronounced neuropathological alteration in
these disorders or in animal models of aging (Cummings and
Benson, 1987; Kurosawa et al., 1989; Mesulam, 2004; Mesulam
et al., 1987). This suggests that age-related decline in certain
cognitive functions putatively mediated by the cholinergic
system may stem, in part, from a failure of normal afferent
regulation of the BFCS. Alterations in hypothalamic, including
orexin, modulation of the cholinergic system is likely to
contribute to these changes. Interestingly, recent evidence
shows that changes in homeostatic measures such as food
intake and body weight may precede, and indeed predict,
subsequent cognitive decline; in some cases, these studies
reveal an association between Alzheimer's disease and unexplained weight loss as many as 10 years prior to the onset of
frank dementia (Buchman et al., 2005; Grundman, 2005; Johnson
et al., 2006). The factors underlying age-related changes in
homeostatic regulation and cognition are assuredly heterogeneous and multifactorial (Chapman et al., 2002; Horwitz et al.,
2002; Wurtman, 1988). However, a failure of brain regions
involved in homeostatic regulation (e.g., the orexin system) to
activate other brain regions (e.g., the BFCS) that mediate the
appropriate behavioral and cognitive responses to homeostatic
challenges such as food or water deprivation may mechanistically link these disparate phenomena.

10.

Conclusion

Hypothalamic regulation of the BFCS represents a pathway by
which interoceptive information gains access to attentional
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mechanisms. Orexin neurons are quantitatively and functionally significant contributors to this pathway. Dysfunction
in orexin–acetylcholine interactions may play a role in the
arousal and attentional deficits that accompany neurodegenerative conditions as diverse as drug addiction and age-related
cognitive decline.
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